Finland· FI-REL-REL63533
Almogran
A almotriptan product containing almotriptan d,l-hydrogen malate, registered in Finland by Abacus Medicine A/S. The same ATC class is registered in 16 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Almotriptan is registered in 16 of 19 countries.
Countries holding a registration under ATC N02CC05 (almotriptan), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Almotriptan · ATC N02CC05
16 / 19 countries
- Belgiumprice
- Canada
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of almotriptan costs, country by country.
Normalised to the WHO defined daily dose (12.5 mg), the median price runs from $1.25 in France to $6.02 in Switzerland — a ×4.8 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Almotriptan · price per daily dose (12.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$6.02
- ES Spain$5.56
- IT Italy$3.29
- FR France$1.25
The record
At a glance
Fimea (Finland)- Active substance
- Almotriptan D,L-hydrogen malate
- Manufacturer
- Abacus Medicine A/S
- Country
- Finland (FI)
- ATC code
- N02CC05
- ATC class
- Almotriptan
- Defined daily dose
- 12.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 2
2 priced- fi_myyntilupa0705306EUR 21.24
- fi_myyntilupa10837812EUR 41.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for almotriptan.
Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Almotriptan · interactions on record
81 records
- 13 severe
- 29 moderate
- 38 info
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Almotriptan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainALMOGRAN 12,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAlmirall S.A.S.
- ItalyALMOGRANBB FARMA S.R.L.
- FranceALMOGRAN 12,5 mg, comprimé pelliculéALMIRALL
- PolandAlmozenZentiva, k.s.
- SwedenAlmogran 12,5 mg Filmdragerad tablettAbacus Medicine A/S
- NetherlandsAlmogran 12,5 mg filmomhulde tablettenOriginalis B.V.
- BelgiumAlmogran 12.5 mgOrifarm
- NorwayAlmogranAlmirall, S.A.
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Belgium · Almogran
- Germany · Almogran, Almotriptan Bei Migräne Heumann
- Spain · Almogran, Almotriptán Cinfa
- France · Almogran, Almotriptan Biogaran
- United Kingdom (Northern Ireland) · Almogran, Almotriptan Accord-Uk
- Greece · Almogran
- Ireland · Almogran
- Italy · Almogran, Almotrex
- Luxembourg · Almogran
- Netherlands · Almogran
- Norway · Almogran, Almotriptan Orifarm
- Poland · Nomigren, Trymigan
- Portugal · Almogran, Almotriptano Galenicum
- Sweden · Almogran, Almotriptan Orifarm
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a6c2f867-6f99-4264-ab32-17e2d0a3ad4b GET /v1/drugs/a6c2f867-6f99-4264-ab32-17e2d0a3ad4b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "12.5",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "mg",
"strength": "12.5 mg",
"atc_label": "almotriptaani",
"ma_number": "44472",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL63533",
"authorised_at": "2025-12-10"
}See everything about almotriptan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.